Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bioengineering
Report Highlights Impact of Recent Entries and New Mechanisms on Rheumatoid Arthritis Treatment Paradigms
August 31st, 2007
MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for pharma and biotech companies with a stake in the market for Rheumatoid Arthritis (RA) therapies. In this report entitled, "MedPredict Thought Leader Insight & Analysis: Rheumatoid Arthritis," physician experts from North America and Europe discuss the expected introduction of IL-6 receptor antagonist Actemra, being co-developed by Roche and Chugai, and how it will impact current treatment paradigms and currently marketed products. "The discussion in this report sets the bar for next generation...
Source: Drug Week (2007-08-31)
|
